Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

已完结 10 由医休发布于 2026/7/23 9:06:17

DOI:10.1056/NEJMOA1606774
作者：M. Reck, D. Rodríguez-Abreu, A. Robinson, R. Hui, T. Cs?szi, A. Fül?p, M. Gottfried, N. Peled, A. Tafreshi, S. Cuffe, M. O'Brien, Suman B. Rao, K. Hotta, M. Leiby, G. Lubiniecki, Shentu Yue, Reshma
文献类型：期刊论文
补充材料：只需要正文
文献链接：https://doi.org/10.1056/NEJMOA1606774

New England Journal of Medicine (NEJM)

Abstract：BACKGROUND Pembrolizumab is a humanized monoclonal antibody against programmed death 1 (PD-1) that has antitumor activity in advanced non-small-cell lung cancer (NSCLC), with increased activ

应助信息

20小时前

立秋

5eb090cd863311f19f1434735aa3bc31.pdf 已采纳

20小时前

Book学术机器人

2026/7/23 9:06:17 未找到该文献，机器人已退出，请等待人工下载

2026/7/23 9:06:17 Book学术AI机器人收到请求，开始寻找文献

2026/7/23 9:06:17 已向机器人发送请求

20小时前

医休发布求助

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:American Physiological Society (APS)Factors involved in fibrosis of colorectal tissue due to chronic ulcerative colitis